Empagliflozin
1245-0202
Phase 3 small_molecule completed
Quick answer
Empagliflozin for Myocardial Infarction is a Phase 3 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Myocardial Infarction
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed